Risako Kohya
Sapporo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.
Journal: Journal of gastroenterology
Published: May 05, 2026
Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.
Journal: Frontiers in nutrition
Published: October 23, 2025
Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.
Journal: Hepatology international
Published: October 22, 2025
Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.
Journal: Journal of cachexia, sarcopenia and muscle
Published: October 20, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Journal: Hepatology international
Published: April 30, 2025
Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: April 02, 2025
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Journal: Targeted oncology
Published: August 14, 2024
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
Journal: JHEP reports : innovation in hepatology
Published: August 04, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: July 23, 2024
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
Journal: Alimentary pharmacology & therapeutics
Published: June 09, 2024
Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
Journal: Frontiers in nutrition
Published: August 04, 2023
Last Updated: 09/26/2026